Anti-PD-1 antibodies and methods for their production and use

Abstract

This application provides anti-PD-L monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof, and / or nucleic acids encoding same, and their uses for upregulating T cell function and enhancing cellular immune responses in the treatment of cancer and other T cell dysfunction.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62545603, filed August 15, 2017, U.S. Provisional Patent Application No. 62524553, filed June 25, 2017, U.S. Provisional Patent Application No. 62524554, filed June 25, 2017, U.S. Provisional Patent Application No. 62524557, filed June 25, 2017, and U.S. Provisional Patent Application No. 62524558, filed June 25, 2017, which are hereby expressly incorporated by reference in their entireties. [Technical field]

[0002] The disclosure herein relates generally to the field of antibodies, and more specifically to the production and use of anti-PD-1 antibodies. [Background technology]

[0003] Cancer is a major health problem worldwide. In the United States alone, there will be an estimated 1,685,210 new cancer diagnoses and 595,690 deaths in 2016 (http: / / www.cancer.gov). Therefore, medicines that can reduce the severity or mortality from cancer are desirable.

[0004] Cancerous tumors may employ various mechanisms to avoid detection and / or destruction by the host immune system. One method utilized by various tumors is to suppress immune T cell responses by expressing PD-1 on the surface of tumor cells. When PD-1 binds to its receptor PD-1 on the surface of T cells, a negative costimulatory signal is sent to the T cells, suppressing them. In this way, tumor cells may evade the T cell-mediated response of the host immune system.

[0005] Drugs that can bind to PD-1 and block negative costimulatory signals from suppressing T cell responses have been shown to enhance the host immune response against cancerous tumors, resulting in beneficial responses in cancer patients (see Iwai et al. J. Biomed. Sci. 24:26 (2017)).

[0006] In the immune system, resting T cells can be activated to respond to antigens through a primary signal delivered via the T cell receptor (TCR) by foreign antigenic peptides presented by antigen-presenting cells (APCs). In addition to this primary signal, there are secondary positive and negative co-stimulatory signals that further influence the T cell response. A secondary positive signal is required to fully activate T cells (Lafferty et al., Ausl. J. Exp. Biol. Med. Sci. 53:27-42 (1975)). A negative secondary signal can result in T cell suppression and tolerance.

[0007] Programmed Death 1 (PD-1) is a member of the CD28 family of receptors and is expressed on T cells and other cell types. PD-1 is one of the routes used to transmit negative secondary signals to T cells. PD-1 is the cell surface ligand glycoprotein of PD-1, and binding to PD-1 has been shown to downregulate T cell activation (Freeman et al. J. Exp. Med. 192: 1027-34 (2000)). PD-1, also known as B7-H1 or CD274, is a 40 kDa type 1 transmembrane protein that has been shown to be expressed in several human cancers and is associated with increased tumor aggressiveness and increased risk of death (Thomson et al. PNAS 101: 17174-9 (2004)). PD-1 expression in cancer is thought to suppress immune responses against tumors through suppression of T cells via interaction with PD-1 (Dong et al. Nat. Med. 8: 793-800 (2002)). As a result, several PD-1 inhibitors are currently being developed or have been developed to enhance T cell activity against tumors for the treatment of cancer.

[0008] Drugs that can bind to PD-1 and block negative costimulatory signals from suppressing T cell responses have been shown to increase host immune responses against cancerous tumors, resulting in beneficial responses for cancer patients (see Reiss et al. Immunotherapy. 6:459-75 (2014)), but the optimal PD-1 binding site and associated affinity for developing the most effective tumor cell-specific anti-PD-1 antibodies for cancer treatment remain unclear. Summary of the Invention

[0009] In one aspect, the present application provides anti-PD-1 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof, and / or nucleic acids encoding same, and their uses for upregulating T cell function and enhancing cellular immune responses in the treatment of cancer and other T cell dysfunction.

[0010] In one embodiment, an isolated monoclonal antibody (mAb) or antigen-binding fragment thereof that specifically binds to human PD-1 is provided. In one embodiment, the isolated mAb or antigen-binding fragment comprises an amino acid sequence having a percentage homology to SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:56, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, or SEQ ID NO:80. The percentage homology is 70%, 80%, 90%, 95%, 98%, or 99% or greater.

[0011] In one embodiment, the isolated mAb or antigen-binding fragment has a binding affinity for human PD-1 with a Kd of 3-40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, or 100 nM or less.

[0012] In one embodiment, the isolated mAb or antigen-binding fragment may exhibit one or more functional properties including, but not limited to, high affinity binding to human PD-1, inhibition of binding of human PD-L1 to PD-1, enhancing T cell activation, stimulating an antibody response, and / or reversing the suppressive function of immune suppressive cells, or a combination thereof. In one embodiment, immune suppressive cells include regulatory cells. In one embodiment, the isolated mAb or antigen-binding fragment may enhance T cell activation via a mechanism or pathway including T cell proliferation, IFN-γ and / or IL-2 secretion, or a combination thereof.

[0013] In one embodiment, the isolated mAb or antigen-binding fragment comprises a human framework region, hi one embodiment, the isolated mAb or antigen-binding fragment is a humanized antibody, a chimeric antibody, or a recombinant antibody.

[0014] In one embodiment, the isolated mAb or antigen-binding fragment is an IgG. In one embodiment, the antigen-binding fragment is an Fv, Fab, F(ab')2, scFV, or scFV2 ​​fragment. In one embodiment, the isolated mAb is a bispecific, trispecific, or multispecific antibody.

[0015] In one embodiment, the application provides an isolated mAb or antigen-binding fragment having an IgG1 heavy chain having an amino acid sequence having a percentage homology to SEQ ID NO:7, SEQ ID NO:15, SEQ ID NO:23, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:47, SEQ ID NO:55, SEQ ID NO:63, SEQ ID NO:71, or SEQ ID NO:79. The percentage homology is greater than or equal to 70%, 80%, 90%, 95%, 98%, or 99%.

[0016] In one embodiment, the application provides an isolated mAb or antigen-binding fragment having a kappa light chain having an amino acid sequence having a percentage homology to SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:27, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:51, SEQ ID NO:59, SEQ ID NO:67, or SEQ ID NO:75. The percentage homology is greater than or equal to 70%, 80%, 90%, 95%, 98%, or 99%.

[0017] In one embodiment, the application provides an isolated mAb or antigen-binding fragment having a variable light chain comprising an amino acid sequence having a percentage homology to SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:36, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:60, SEQ ID NO:68, or SEQ ID NO:76. The percentage homology is greater than or equal to 70%, 80%, 90%, 95%, 98%, or 99%.

[0018] In one embodiment, the application provides an isolated mAb or antigen-binding fragment having a variable heavy chain having an amino acid sequence having a percentage homology to SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:40, SEQ ID NO:48, SEQ ID NO:56, SEQ ID NO:64, and SEQ ID NO:72, or SEQ ID NO:80. The percentage homology is greater than or equal to 70%, 80%, 90%, 95%, 98%, or 99%.

[0019] In one embodiment, an isolated nucleic acid is provided that encodes an isolated mAB or antigen-binding fragment disclosed herein. In one embodiment, the isolated nucleic acid encodes an amino acid sequence having a percentage homology to: 1) an IgG1 heavy chain having the amino acid sequence of SEQ ID NO:7, SEQ ID NO:15, SEQ ID NO:23, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:47, SEQ ID NO:55, SEQ ID NO:63, SEQ ID NO:71, or SEQ ID NO:79; 2) a kappa light chain having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:27, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:51, SEQ ID NO:59, SEQ ID NO:67, or SEQ ID NO:75; 3) a variable light chain having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:36, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:60, SEQ ID NO:68, or SEQ ID NO:76; 4) a variable heavy chain having the amino acid sequence of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:40, SEQ ID NO:48, SEQ ID NO:56, SEQ ID NO:64, SEQ ID NO:72, or SEQ ID NO:80. The percentage homology may be greater than or equal to 70%, 80%, 90%, 95%, 98%, or 99%.

[0020] In one embodiment, an expression vector is provided comprising an isolated nucleic acid encoding an amino acid sequence disclosed herein. In one embodiment, the expression vector is expressible in a cell.

[0021] In one embodiment, the present application provides a host cell comprising a nucleic acid encoding an amino acid sequence disclosed herein. In one embodiment, the present application provides a host cell comprising an expression vector comprising one or more of the nucleic acids encoding an amino acid sequence disclosed herein. In one embodiment, the host cell can be a prokaryotic or eukaryotic cell.

[0022] In another aspect, the present application provides a method for producing an antibody. In one embodiment, the method comprises using a host cell as described above. The method comprises providing a host cell comprising an expression vector expressible in the host cell, the expression vector comprising a nucleic acid encoding at least a portion of the isolated mAb or antigen-binding fragment, or peptide disclosed herein, to produce an antibody by expression of the nucleic acid.

[0023] The present application further provides an immunoconjugate comprising a drug unit or an imaging agent linked to an mAb or antigen-binding fragment disclosed herein. The immunoconjugate may comprise a drug unit and an isolated mAb or antigen-binding fragment disclosed herein.

[0024] The linker may be cleavable or non-cleavable. In one embodiment, the linker comprises an ester bond, an ether bond, an amine bond, an amide bond, a disulfide bond, an imide bond, a sulfone bond, a phosphate bond, a phosphorus ester bond, a peptide bond, a hydrazone bond, or a combination thereof. In one embodiment, the linker comprises a hydrophobic poly(ethylene glycol) linker.

[0025] In one embodiment, the Drug Unit in the immunoconjugate is a chemotherapeutic agent, a growth inhibitory agent, a toxin, or a radioisotope. In one embodiment, the Drug Unit comprises a cytotoxic agent selected from the group of a calicheamicin, an antimitotic agent, or a combination thereof. In one embodiment, the Drug Unit comprises ozogamicin, monomethylauristatin E, emtansine, a derivative or combination thereof.

[0026] In one embodiment, the drug unit is selected from a cytotoxic agent, an immunomodulatory agent, an imaging agent, or a combination thereof. In one embodiment, the cytotoxic agent is selected from a growth inhibitory agent or a chemotherapeutic agent selected from the group of tubulin binding agents, DNA intercalators, DNA alkylators, enzyme inhibitors, immunomodulators, antimetabolites, radioisotopes, or a combination thereof. In one embodiment, the cytotoxic agent is selected from calicheamicin, ozogamicin, monomethyl auristatin E, emtansine, derivatives or combinations thereof. In one embodiment, the immunomodulatory agent activates or suppresses immune cells, T cells, NK cells, B cells, macrophages, or dendritic cells.

[0027] In one embodiment, the imaging agent may be a radionuclide, a fluorescent agent, a quantum dot, or a combination thereof.

[0028] The present application further provides a pharmaceutical composition. In one embodiment, the pharmaceutical composition comprises an isolated mAb or antigen-binding fragment disclosed herein and a pharma- ceutical acceptable carrier. In one embodiment, the pharmaceutical composition provides an immunoconjugate disclosed herein and a pharma- ceutical acceptable carrier.

[0029] In one embodiment, the pharmaceutical composition further comprises a chemotherapeutic agent, growth inhibitory agent, or drug unit selected from the group of a calicheamicin, an antimitotic agent, a toxin, a radioisotope, a therapeutic agent, or a combination thereof. In one embodiment, the therapeutic agent comprises an antibody, a chemotherapeutic agent, an enzyme, or a combination thereof. In one embodiment, the therapeutic agent comprises an anti-estrogen agent, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a cell cycle inhibitor, a DNA, RNA, or protein synthesis inhibitor, a RAS inhibitor, or a combination thereof.

[0030] In one embodiment, a method is provided for treating a subject having cancer comprising administering to the subject an effective amount of an isolated mAb or antigen-binding fragment disclosed herein. In one embodiment, the method comprises directly injecting into the tumor site an effective amount of the monoclonal antibodies, antigen-binding fragments thereof, and immunoconjugates disclosed herein.

[0031] In one embodiment, the cancer comprises cells that express PD-1. In one embodiment, the cancer may be breast cancer, colon cancer, pancreatic cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, non-small cell lung cancer, glioma, esophageal cancer, nasopharyngeal cancer, anal cancer, rectal cancer, gastric cancer, bladder cancer, cervical cancer, or brain cancer.

[0032] In one embodiment, the method of treating a subject with cancer may further comprise co-administering an effective amount of a therapeutic agent. In one embodiment, the therapeutic agent comprises an antibody, an enzyme, or a combination thereof. In one embodiment, the therapeutic agent may comprise a chemotherapeutic agent, a growth inhibitor, or a drug unit selected from the group of a calicheamicin, a mitotic inhibitor, a radioisotope, a toxin, or a combination thereof. In one embodiment, the therapeutic agent comprises an anti-estrogen, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a cell cycle inhibitor, a DNA, RNA, or protein synthesis inhibitor, a RAS inhibitor, or a combination thereof. In one embodiment, the therapeutic agent comprises a checkpoint inhibitor.

[0033] In one embodiment, the therapeutic agent includes capecitabine, cisplatin, cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, cyclophosphamide, mustine, vincristine, procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, epirubicin, pemetrexed, folinic acid, gemcitabine, oxaliplatin, irinotecan, topotecan, camptothecin, docetaxel, paclitaxel, fulvestrant, tamoxifen, letrozole, exemestane, anastrozole, aminoglycoside, rifabutin ... These may include lutethimide, testolactone, vorozole, formestane, fadrozole, erlotinib, lafatinib, dasatinib, gefitinib, osimertinib, vandertanib, afatinib, imatinib, pazopinib, lapatinib, sunitinib, nilotinib, sorafenib, nab-palitaxel, everolimus, temsirolimus, dabrafenib, vemurafenib, trametinib, vintafolide, apatinib, crizotinib, periforsine, olaparib, bortezomib, tofacitinib, trastuzumab, derivatives or combinations thereof.

[0034] In some embodiments, the subject to be treated is a human. In one embodiment, a solution is provided that comprises an effective concentration of an isolated mAb or antigen-binding fragment disclosed herein, wherein the solution is the plasma of the subject.

[0035] Still other embodiments will become readily apparent to those skilled in the art from the following detailed description. The embodiments are described herein for the purpose of illustrating the best mode contemplated. As will be understood, other different embodiments are possible, and the details of some of the embodiments are capable of modification in various obvious respects, all without departing from the spirit and scope thereof. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature, and not as restrictive. [Brief description of the drawings]

[0036] The preferred embodiments according to the present application will now be described with reference to the drawings, in which like reference numbers refer to like elements, and in which:

[0037] [Figure 1] Figure 1 shows an example of a PD-1 binding ELISA performed on B cell culture plate supernatants. Shaded wells indicate wells identified as positive for anti-PD-1 antibodies. [Diagram 2] Figure 2 shows an example of a BioLayer Interferometry analysis of the ability of antibody supernatants to block the binding between PD-1 and PD-1. The black trace uses a blocking antibody supernatant, and the grey trace uses a non-blocking antibody supernatant. [Diagram 3] Figure 3 shows a biolayer interference analysis of the ability of antibodies AB6-AB10 to block binding between PD-1 and PD-1. Starting with PD-1 binding, followed by baseline and PD-1 binding. The negative control is an anti-PD-1 antibody that can bind to PD-1 but does not block binding between PD-1 and PD-1. [Figure 4] Figure 4 shows an example of binding kinetics data for two anti-PD-1 antibodies binding to PD-1. The data shown show 5 min of association followed by 15 min of dissociation at various concentrations of PD-1. [Diagram 5] Figure 5 shows humanized antibodies binding to cell surface expressed PD-1. Data points show median fluorescence intensity (MFI) in the AF647 channel after gating on live cells. Nonlinear regression methods were used to fit curves to each data set. Error bars represent standard deviation of duplicate samples. [Figure 6] Figure 6 shows antibody-mediated blocking of huPD-1 / huPD-1 interaction. Ability of humanized anti-PD-1 antibodies to block PD-1 binding to Jurkat / huPD-1 cell line by FACS. Data show median fluorescence intensity (MFI) in the APC channel after gating on live cells. Error bars represent standard deviation of duplicate samples. [Figure 7]Figure 7 shows antibody-mediated blocking of huPD-1 / huPD-L2 interaction. The ability of humanized anti-PD-1 antibodies to block PD-L2 binding to Jurkat / huPD-1 cell line by FACS. Data show median fluorescence intensity (MFI) in the APC channel after gating on live cells. Error bars represent standard deviation of duplicate samples. [Figure 8] Figure 8 shows the effect of humanized PD-1 antibodies on T cell activation. IL-2 production from human PBMC cells in response to Staphylococcal enterotoxin B in the presence of humanized anti-PD-1 antibodies or control human IgG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The present application provides, inter alia, isolated antibodies, antigen-binding fragments thereof, methods for making such antibodies or fragments, bispecific or multispecific molecules, antibody-drug conjugates and / or immunoconjugates comprised of such antibodies or antigen-binding fragments, pharmaceutical compositions comprising the antibodies, bispecific or multispecific molecules, antibody-drug conjugates and / or immunoconjugates, and methods for treating cancer using the mAbs and antigen-binding fragments thereof disclosed herein.

[0039] In one aspect, the present application provides an isolated monoclonal antibody or antigen-binding fragment thereof having binding specificity for human PD-1. The antibody or antigen-binding fragment thereof exhibits one or more desirable functional properties, such as high affinity binding to PD-1, the ability to inhibit binding of PD-1 to PD-L1, the ability to enhance T cell activation, including proliferation, IFN-γ and / or IL-2 secretion, the ability to stimulate an antibody response, and / or the ability to reverse the suppressive function of immune suppressor cells, such as regulatory T cells. In one embodiment, the antibody or antigen-binding fragment thereof may be derived from structural features, such as specific heavy and light chain amino acid sequences, and / or complementarity determining regions (CDRs) composed of specific amino acid sequences.

[0040] The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, and antibody fragments (e.g., Fab, F(ab')2, and Fv), so long as they exhibit the desired biological activity. In some embodiments, antibodies may be monoclonal, polyclonal, chimeric, single chain, bispecific or bipotent, and humanized antibodies, and active fragments thereof. Examples of active fragments of molecules that bind known antigens include Fab, F(ab')2, scFv, and Fv fragments, including the products of a Fab immunoglobulin expression library, as well as epitope-binding fragments of any of the above antibodies and fragments. In some embodiments, antibodies may include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain a binding site that has immunological binding specificity for an antigen. Immunoglobulins are any type (IgG, IgM, IgD, IgE, IgA, and IgY) or class (IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule. In one embodiment, an antibody may be a whole antibody and any antigen-binding fragment derived from a whole antibody. A typical antibody typically refers to a heterotetrameric protein having two heavy (H) chains and two light (L) chains. Each heavy chain is composed of a heavy chain variable domain (abbreviated as VH) and a heavy chain constant domain. Each light chain is composed of a light chain variable domain (abbreviated as VL) and a light chain constant domain. The VH and VL regions can be further subdivided into domains of hypervariable complementarity determining regions (CDRs) and more conserved regions called framework regions (FRs). Each variable domain (VH or VL) is typically composed of three CDRs and four FRs arranged in the following order: From the amino terminus to the carboxy terminus are FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. Within the variable regions of the light and heavy chains are binding domains that interact with an antigen.

[0041] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies; that is, the individual antibodies comprising the population are identical except for naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by a hybridoma culture and are uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by a particular method. For example, the monoclonal antibodies to be used in accordance with the present application may be made by the hybridoma method first described by Kohler & Milstein, Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).

[0042] In one embodiment, monoclonal antibodies may include "chimeric" antibodies (immunoglobulins) in which portions of the heavy and / or light chains are identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as the desired biological activity is exhibited (US Pat. No. 4,816,567, and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855

[1984] ).

[0043] Monoclonal antibodies can be produced using a variety of methods, including mouse hybridoma or phage display (for review, see Siegel. Transfus. Clin. Biol. 9:15-22 (2002)), or by molecular cloning of antibodies directly from primary B cells (see Tiller. New Biotechnol. 28:453-7 (2011)). In the present disclosure, antibodies were generated by immunizing rabbits with both human PD-1 protein and cells transiently expressing human PD-1 on their cell surface. Rabbits are known to generate antibodies with high affinity, diversity, and specificity (Weber et al. Exp. Mol. Med. 49:e305). B cells from immunized animals were cultured in vitro and screened for production of anti-PD-1 antibodies. Antibody variable genes were isolated using recombinant DNA techniques, and the resulting antibodies were recombinantly expressed and further screened for desired characteristics such as the ability to inhibit PD-1 binding to PD-1, the ability to bind to non-human primate PD-1, the ability to enhance human T cell activation, etc. This general method of antibody discovery is similar to that described by Seeber et al. PLOS One. 9:e86184 (2014).

[0044] The term "antigen or epitope binding portion or fragment" refers to a fragment of an antibody capable of binding to an antigen (in this case PD-1). These fragments may be capable of antigen-binding functions of the intact antibody as well as additional functions. Examples of binding fragments include, but are not limited to, single-chain Fv fragments (scFv), consisting of the VL and VH domains of a single arm of an antibody connected to a single polypeptide chain by a synthetic linker, or Fab fragments, which are monovalent fragments consisting of the VL, constant light (CL), VH, and constant heavy 1 (CH1) domains. Antibody fragments are even smaller subfragments and can consist of domains as small as a single CDR domain, particularly the CDR3 region from either the VL and / or VH domain (see, e.g., Beiboer et al., J. Mol. Biol. 296:833-49 (2000)). Antibody fragments are produced using conventional methods known to those of skill in the art. Antibody fragments can be screened for utility using the same techniques used for intact antibodies.

[0045] "Antigen or epitope-binding fragments" may be derived from the antibodies of the present application by a number of techniques known in the art. For example, purified monoclonal antibodies can be cleaved with an enzyme such as pepsin and subjected to HPLC gel filtration. Appropriate fractions containing Fab fragments can then be collected and concentrated, such as by membrane filtration. For further description of general techniques for isolation of active fragments of antibodies, see, e.g., Khaw, BA et al. J. Nucl. Med. 23:1011-1019 (1982); Rousseaux et al. Methods Enzymology, 121:663-69, Academic Press, 1986.

[0046] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment produces an F(ab')2 fragment that has two antigen-binding sites and is capable of cross-linking antigen.

[0047] Fab fragments also contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine ​​residues of the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0048] An "Fv" is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In this configuration, the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, a single variable domain (or half of an Fv containing only three CDRs specific for an antigen) can also recognize and bind antigen, although with a lower affinity than the entire binding site.

[0049] The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda (λ), based on the amino acid sequences of their constant domains.

[0050] Depending on the amino acid sequence of the constant domain of the heavy chain, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, IgM, and some of these can be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, IgG-4, IgA-1 and IgA-2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, delta, epsilon, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.

[0051] "Humanized antibody" refers to a type of engineered antibody that has CDRs derived from a non-human donor immunoglobulin, with the remaining immunoglobulin-derived portions of the molecule derived from one (or more) human immunoglobulins. Additionally, framework support residues may be altered to retain binding affinity. Methods for obtaining "humanized antibodies" are well known to those skilled in the art. (See, e.g., Queen et al., Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al., Bio / Technology, 9:421 (1991)). "Humanized antibodies" can also be obtained by genetic engineering approaches that allow the production of affinity-matured human-like polyclonal antibodies in large animals, such as rabbits (see, e.g., US Pat. No. 7,129,084).

[0052] As used herein, the terms "polypeptide," "peptide," and "protein" are interchangeable and defined to mean a biomolecule composed of amino acids linked by peptide bonds.

[0053] As used herein, the terms "a," "an," and "the" are defined to mean "one or more" and include the plural forms unless the context is inappropriate.

[0054] "Isolated" refers to a biological molecule that is free from at least some of the components with which it naturally occurs. "Isolated", when used to describe various polypeptides disclosed herein, refers to a polypeptide that has been identified and separated and / or recovered from the cell or cell culture in which it is expressed. Typically, an isolated polypeptide is prepared by at least one purification step. "Isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigen specificities.

[0055] By "recombinant" it is meant that the antibody is produced using recombinant nucleic acid techniques in an exogenous host cell.

[0056] The term "antigen" refers to an entity or fragment thereof that is capable of eliciting an immune response in an organism, particularly an animal, more particularly a mammal, including a human. The term includes immunogens and regions thereof that are responsible for antigenic or antigenic determinants.

[0057] The term "immunogenic" as used herein also refers to a substance that induces or enhances the production of antibodies, T cells or other reactive immune cells against the immunogenic agent and contributes to the immune response in humans or animals. An immune response occurs when an individual produces sufficient antibodies, T cells and other reactive immune cells against the administered immunogenic composition of the present application to alleviate or ameliorate the disorder being treated.

[0058] "Specific binding" or "specifically binds" or "specific" for a particular antigen or epitope refers to binding that is distinct from non-specific interactions. Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule, which is generally a molecule of similar structure that has no binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.

[0059] Specific binding to a particular antigen or epitope is, for example, at least about 10 -4 M, at least about 10 -5 M, at least about 10 -6 M, at least about 10 -7 M, at least about 10 -8 M, at least about 10 -9 M, at least about 10 -10 M, at least about 10 -11 M, at least about 10 -12 M, or greater, for an antigen or epitope, where KD refers to the off-rate of a particular antibody-antigen interaction. In some embodiments, an antibody that specifically binds to an antigen may have a KD for the antigen or epitope that is 20-, 50-, 100-, 500-, 1000-, 5000-, 10000-, or greater than that of a control molecule.

[0060] Specific binding to a particular antigen or epitope can also be exhibited by an antibody having a K A or K A for the antigen or epitope that is at least 20-, 50-, 100-, 500-, 1000-, 5000-, 10000-, or greater than that for a control epitope, where K A or K A refers to the association rate of a particular antibody-antigen interaction.

[0061] The "homology" between two sequences is determined by sequence identity. When the two sequences compared to each other are different in length, sequence identity preferably relates to the percentage of nucleotide residues of the shorter sequence that are identical to the nucleotide residues of the longer sequence. Sequence identity can be conventionally determined using computer programs. Deviations that appear in the comparison of a given sequence with the above sequences of this application can be caused by, for example, additions, deletions, substitutions, insertions or recombinations.

[0062] In another aspect, the present application provides pharmaceutical compositions comprising the antibodies, antigen-binding fragments, and immunoconjugates thereof. Formulation of pharmaceutical compositions can be accomplished according to standard methodologies known to those skilled in the art.

[0063] The antibodies of the present application can be prepared in a physiologically acceptable formulation and can include pharma- ceutically acceptable carriers, diluents, and / or excipients using known techniques. For example, the antibodies of the present application and described herein, including antibodies, including functionally equivalent antibodies or functional portions thereof, particularly monoclonal antibodies, including functionally equivalent antibodies or functional portions thereof, are combined with pharma- ceutically acceptable carriers, diluents, and / or excipients to form a therapeutic composition.

[0064] For the formulation of compositions suitable for administration to a subject, such as a human patient in need of treatment, the antibodies disclosed herein can be mixed or combined with pharma- ceutically acceptable carriers known in the art, depending on the route of administration selected. There are no particular limitations on the mode of application of the antibodies disclosed herein, and the selection of an appropriate route of administration and an appropriate composition is known in the art without undue experimentation.

[0065] Suitable pharmaceutical carriers, diluents and / or excipients are well known in the art and include, for example, phosphate buffered saline, water, emulsions such as oil / water emulsions.

[0066] "Pharmaceutically acceptable" refers to those compounds, materials, compositions, and dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human or animals without undue toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Formulation of the pharmaceutical compositions of the present application can be accomplished according to standard methodology known to those of skill in the art.

[0067] In another aspect, the application provides a method of treating a subject using an anti-PD-1 antibody or other molecule disclosed herein. In one embodiment, the method may be used to inhibit tumor cell proliferation. In one embodiment, the method may be used to stimulate a protective autoimmune response, modify an immune response, or stimulate an antigen-specific immune response. In one embodiment, the method comprises administering to a subject in need of such treatment an effective amount of a mAB, antigen-binding fragment, or composition disclosed herein.

[0068] The composition may be administered to the subject in a suitable pharma- ceutically effective dose in solid, liquid or aerosol form. Examples of solid compositions include pills, creams, and implantable dosage units. Pills may be administered orally. Therapeutic creams may be administered topically. Implantable dosage units may be administered locally, e.g., at the tumor site, or may be implanted, e.g., subcutaneously, for systematic release of the therapeutic composition. Examples of liquid compositions include formulations suitable for injection intramuscularly, subcutaneously, intravenously, intraarterially, and formulations for topical and intraocular administration. Examples of aerosol formulations include inhalation formulations for administration to the lungs.

[0069] The composition may be administered by standard routes of administration. Typically, the composition may be administered by topical, oral, rectal, nasal, intradermal, intraperitoneal, or parenteral (e.g., intravenous, subcutaneous, or intramuscular) routes. In one embodiment, administration may be parenteral, e.g., intravenous. Formulations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Non-aqueous solvents include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable organic esters such as ethyl oleate. Aqueous solvents may be selected from the group consisting of water, alcoholic / aqueous solutions, emulsions or suspensions including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

[0070] In one embodiment, the composition may be incorporated into a sustained release matrix, such as a biodegradable polymer, which is implanted near where delivery is desired, for example, at a tumor site. This method includes administration of a single dose, administration of repeated doses at predetermined time intervals, and sustained administration for a predetermined period of time.

[0071] A sustained release matrix, as used herein, is a matrix made of materials, usually polymers, that are degradable by enzymatic or acid / base hydrolysis or dissolution. Once inserted into the body, the matrix is ​​acted upon by enzymes and body fluids. The sustained release matrix is ​​desirably selected from biocompatible materials such as liposomes, polylactides (polylactide acids), polyglycolides (polymers of glycolic acid), polylactide-co-glycolides (copolymers of lactic and glycolic acid), polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinylpropylene, polyvinylpyrrolidone, and silicones. A preferred biodegradable matrix is ​​a matrix of either polylactide, polyglycolide, or polylactide-co-glycolide (copolymers of lactic and glycolic acid).

[0072] Those skilled in the art will know that the dosage of the composition will depend on a variety of factors, such as, for example, the condition being treated, the particular composition used, the patient's weight, size, sex, general health, and other clinical factors such as body surface area, the particular compound or composition being administered, other drugs being administered concomitantly, and the route of administration.

[0073] The term "therapeutically effective amount" refers to an amount of an antibody that, when administered to a human or animal, elicits a response sufficient to provide a therapeutic effect in that human or animal. The effective amount is readily determined by one of ordinary skill in the art following routine procedures.

[0074] The compositions may be administered in combination with other compositions containing biologically active substances or compounds. Examples of biologically active substances or compounds include, but are not limited to, compounds against oxidative stress, anti-apoptotic compounds, metal chelators, inhibitors of DNA repair such as pirenzepine and metabolites, 3-amino-1-propanesulfonic acid (3APS), 1,3-propanedisulfonate (1,3PDS), secretase activators, β- and γ-secretase inhibitors, tau protein, neurotransmitters, β-sheet breakers, anti-inflammatory molecules, such as clozapine, ziprasidone, risperidone, aripiprazole, or olanzapine. atypical antipsychotics, or cholinesterase inhibitors (ChEIs) such as tacrine, rivastigmine, donepezil, and / or galantamine, and other drugs and nutritional supplements such as, for example, vitamin B12, cysteine, precursors of acetylcholine, lecithin, choline, ginkgo, acetyl-L-carnitine, idebenone, propentofylline, or xanthine derivatives, together with the antibody of the present application, and optionally including a pharmacokinetic or physiologically acceptable carrier and / or diluent and / or excipient and instructions for treating the disease.

[0075] The pharmaceutical composition may further comprise a proteinaceous carrier, such as, for example, serum albumin or immunoglobulin, particularly of human origin. Depending on the intended use, further bioactive agents may be present in the pharmaceutical composition of the present application. The proteinaceous pharmacoactive substance may be present in an amount of 1 ng to 10 mg per dose. In general, the dosing regime should be in the range of 0.1 μg to 10 mg, particularly in the range of 1.0 μg to 1.0 mg, more particularly in the range of 1.0 μg to 100 μg of the antibody of the present application, all individual numbers within these ranges being part of the present application. If the administration is by continuous infusion, a more suitable dose is in the range of 0.01 μg to 10 mg units per kilogram of body weight per hour, all individual numbers within these ranges being part of the present application.

[0076] The present application may be more readily understood by reference to the following detailed description of certain embodiments contained herein. Although the present application has been described with reference to certain details of certain embodiments thereof, such detailed description should not be considered as a limitation on the scope of the disclosure. All references cited or referred to in this application are specifically incorporated herein by reference in their entirety. EXAMPLES

[0077] Example 1: Generation of anti-PD-1 antibodies Monoclonal antibodies against human PD-1 were generated by immunizing New Zealand white rabbits. The first immunization was performed subcutaneously with 100 μg of recombinant human PD-L1 extracellular domain mixed 1:1 v / v with complete Freund's adjuvant. Booster immunizations were performed at weeks 3, 6, and 8 with 50 μg of antigen in incomplete Freund's adjuvant. In addition to the antigen, 1 × 10 IgG1 cells transiently transfected to express full-length human PD-1 were also administered at weeks 3, 6, and 8. 6 The animals were boosted with HEK-293 cells.

[0078] At week 8, the animals' sera were tested for anti-PD-1 titers by ELISA. 96-well plates were coated overnight by passive adsorption at 4°C using goat anti-rabbit IgG antibody (Jackson ImmunoResearch). The coated wells were washed and blocked with 1% milk for 1 h at room temperature, followed by incubation with human PD-1 extracellular domain-human Fc domain fusion protein for 1 h at room temperature. After washing, undiluted serum was added to the wells and serially diluted 1:10 across the plate for a total of 7 wells each. After incubation for 1 h at room temperature, the plates were washed and incubated with goat anti-human IgG Fc-specific horseradish peroxidase-conjugated antibody (Jackson ImmunoResearch). The plates were washed and then incubated with Ultra TMB Substrate (Fisher Scientific) for 30 min at room temperature. The signal in the wells was detected by an absorbance plate reader at a wavelength of 450 nm to generate a titer curve. The anti-PD-1 titers are compared to an ELISA performed with sera from the same animals obtained before immunization.

[0079] At week 9, rabbits with significantly higher anti-PD-1 titers were harvested and selected for monoclonal antibody production.

[0080] Anti-PD-1 positive rabbit B cells were harvested from the spleen and lymph nodes 12 weeks after the first immunization. B cells were cultured in 96-well plates for 1 week to allow differentiation into plasma cells and secretion of antibodies. Supernatants from these plasma cell cultures were screened by ELISA as described above for the presence of PD-1 specific antibodies as shown in Figure 1.

[0081] B cells secreting anti-PD-1 antibodies were isolated from positive wells using magnetic capture. Briefly, streptavidin magnetic beads (ThermoFisher Scientific) were coated with biotin-conjugated human PD-1 extracellular domain protein. The coated beads were incubated with cells from anti-PD-1 positive wells. The bead-cell complex was washed using a magnet to remove any non-specific cells, and the bead-cell complex was added directly to a tube containing the RT-PCR master mix.

[0082] The light and heavy chain variable sequences were amplified by multiplex RT-PCR using degenerate primers designed to anneal to the leader sequences and constant regions of rabbit IgG and rabbit kappa sequences. Secondary PCR was performed separately for the light and heavy chains using nested primers containing restriction sites. The amplicons from the variable heavy chain PCR were cloned into an expression vector containing human IgG1. The light chain amplicons were cloned into an expression vector containing human IgK. The resulting clones were sequenced and analyzed.

[0083] The heavy and light chain expression plasmids generated from each well were transiently co-transfected into HEK-293 cells to produce rabbit / human chimeric antibodies, and the resulting supernatant containing the recombinant antibodies was clarified by centrifugation.

[0084] Recombinant antibody supernatants were confirmed to contain anti-PD-1 antibodies using biolayer interferometry on a ForteBio Octet Red 96 instrument. Antibody in the supernatant was captured using an anti-human Fc biosensor (Pall ForteBio). Binding to PD-1 was monitored by real-time interferometry by placing the biosensor in a well containing recombinant human PD-1 extracellular domain protein. Dissociation was measured after transferring the biosensor to a well containing 10X kinetics buffer (Pall ForteBio). Interferometric data were analyzed using software provided by the manufacturer.

[0085] Humanized versions of the anti-PD-1 antibodies AB1-AB5 have been made, which are indicated by the addition of "HU" after the original name. For example, AB1HU is a humanized version of antibody AB1.

[0086] Example 2: Binding affinity of anti-PD-1 antibodies The binding kinetics of selected anti-PD-1 antibodies AB1-AB5 and AB1HU-AB5HU were measured by biolayer interference analysis on a ForteBio Octet Red 96 instrument. First, purified antibodies were generated by protein A chromatography using antibody supernatants from transiently transfected HEK-293. The assay was performed by immobilizing purified antibodies on an anti-human Fc biosensor. Binding and dissociation of PD-1 to the biosensor was then observed at various concentrations of PD-1. Specifically, eight anti-human Fc biosensors were placed in wells containing the same purified antibodies for 5 min. The biosensors were equilibrated in kinetics buffer (Pall ForteBio) for 1 min to establish a baseline. Binding of PD-1 was observed by placing the biosensors in wells containing various concentrations of human PD-1 extracellular domain for 5 min. The biosensors were transferred to kinetics buffer and the interference signal was monitored for 15 min, after which dissociation was measured. All steps of the assay were carried out at 30° C. with shaking at 1000 RPM. On and off rates (k and k) and the equilibrium binding constant K were determined using the software provided by the manufacturer and fitted using a 1:1 binding global fit model including several tested concentrations. The results of the kinetic studies are shown in Table 1. [Table 1]

[0087] Example 3: Antibodies that bind to the cell surface expressing PD-1 The human PD-1 gene was subcloned into the pcDNA3.1 mammalian expression vector and transfected into the Jurkat human T cell line. A clonal cell population expressing high levels of huPD-1 was generated by G418 drug selection and single cell sorting. This Jurkat / huPD-1 clonal cell line was labeled with FVS520 viability dye (BD Biosciences, 1:2000 dilution) for 15 min at room temperature. The labeled cells were then diluted in FACS buffer (2% FBS in PBS), added to a V-bottom 96-well plate (50,000 cells per well) and stained with 0–25 nM anti-huPD1 or isotype control antibody for 30 min on ice. The cells were washed to remove excess primary antibody and then labeled with Alexa luor 647-conjugated goat anti-human Fc secondary antibody (Jackson Immunoresearch, 1:1600 dilution) for 20 min on ice. The labeled cells were then washed with FACS buffer and then subjected to a BD FACSCalibur flow cytometer equipped with a Cytek AMS plate loader system. The results of AB1HU-AB5HU in this assay are shown in Figure 2. Data points indicate the median fluorescence intensity (MFI) in the AF647 channel after gating on live cells. A nonlinear regression method was used to fit a curve to each data set. Error bars represent the standard deviation of duplicate samples.

[0088] Example 4: Antibody-mediated blocking of huPD-1 / huPD-L1 interaction Jurkat / huPD-1 clonal cell lines were labeled with FVS520 viability dye (BD Biosciences, 1:2000 dilution) for 15 minutes at room temperature. The labeled cells were then diluted in FACS buffer (2% FBS in PBS), added to a V-bottom 96-well plate (50,000 cells per well) and stained with 0-100 nM anti-huPD1 or isotype control antibody for 30 minutes on ice. The cells were washed to remove excess antibody and then labeled with 15 ug / ml His-tag purified, monobiotinylated huPD-1 for 30 minutes on ice. The cells were washed again with FACS buffer and labeled with 0.25 ug / ml APC-conjugated streptavidin for 20 minutes on ice. The cells were washed again before being subjected to a BD FACSCalibur flow cytometer equipped with a Cytek AMS plate loader system. The results of AB1HU-AB5HU from this assay are shown in Figure 3. Also shown is the median fluorescence intensity (MFI) in the APC channel after gating on live cells. Error bars represent the standard deviation of duplicate samples.

[0089] Example 5: Antibody-mediated blocking of huPD-1 / huPD-L2 interaction Jurkat / huPD-1 clonal cell lines were labeled with FVS520 viability dye (BD Biosciences, 1:2000 dilution) for 15 minutes at room temperature. The labeled cells were then diluted in FACS buffer (2% FBS in PBS), added to a V-bottom 96-well plate (50,000 cells per well) and stained with 0-100 nM anti-huPD1 or isotype control antibody for 30 minutes on ice. The cells were washed to remove excess antibody and then labeled with 15 ug / ml His-tag purified, monobiotinylated huPD-L2 for 30 minutes on ice. The cells were washed with FACS buffer and then labeled with 0.25 ug / ml APC-conjugated streptavidin for 20 minutes on ice. The cells were washed again with FACS buffer before being subjected to a FACSCalibur flow cytometer equipped with a Cytek AMS plate loader system. The results of AB1HU-AB5HU in this assay are shown in Figure 7. Data show median fluorescence intensity (MFI) in the APC channel after gating on live cells. Error bars represent standard deviation of duplicate samples.

[0090] Example 6: Effect of PD-1 antibodies on human T cell activation Human PBMCs (100,000 cells / well) from healthy donors were mixed with 100 ng / ml superantigen (Staphylococcal enterotoxin B (SEB), Toxin Technology, Inc.) and 0–100 nM anti-huPD1 or isotype control antibody in complete RPMI medium in flat-bottom 96-well plates. After incubating the assay plates for 3 days in a 37 °C, 5% CO2 incubator, supernatant samples were tested for the presence of huIL-2 using a commercially available kit (R&D Systems). The results of AB1HU-AB5HU in this assay are shown in Figure 4. Data points represent the huIL-2 values ​​of the tested antibodies, interpolated from a standard ELISA curve. A nonlinear regression method was used to fit the curves to each data set. Error bars represent the standard deviation of quadruplicate samples.

[0091] Although the present application has been particularly shown and described with reference to embodiments thereof, those skilled in the art will recognize that the foregoing and other changes in form and detail may be made therein without departing from the spirit and scope thereof. All references cited or referred to in this application are incorporated herein by reference in their entirety.

[0092] Sequence Listing SI-11 anti-PD-1 antibody sequence SEQ ID NO:1 AB1 chimeric light chain full length nucleic acid sequence CAAGTGCTGACCCAGACTGCATCGTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAGTTGCCAGTCCAGTCAGAGTTTTAGATAACAACTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCCATGCTCCTGATCTATACAGTATCCACTCTGGCATCTGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGGCGTGCAGTGACGATGCTCACTTACTACTGTCAAGGCACTTATTATAGTAGTGGTTGGAACTTTGCTTTCGGCGGAGGGACCGAGGTGGTC GTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT அக்க்கியுக்க்கு2 AB1 chimeric light chain variable light chain nucleic acid sequence CAAGTGCTGACCCAGACTGCATCGTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAGTTGCCAGTCCAGTCAGAGTGTTATGATAACAACTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCCATGCTCCTGATCTATACAGTATCCACTCTGG CATCTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTCAAGGCACTTATTATAGTAGTGGTTGGAACTTTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA அக்க்கியுக்க்கு3 Full amino acid sequence of the AB1 chimeric light chain. The human kappa constant domain is underlined. QVLTQTASSVSAAVGGTVTISCQSSQSVYDNNWLAWYQQKPGQPPMLLIYTVSTLASGVSSRFKGSGSGTQFTLTISGVQCDDAATYYCQGTYYSSGWNFAFGGGTEVVVK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 4 AB1 chimeric light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. QVLTQTASSVSAAVGGTVTISC QSSQSVYDNNWLA WYQQKPGQPMLLIY TVSTLAS GVSSRFKGSGSGTQFTLTISGVQCDDAATYYC QGTYYSSGWNFA FGGGTEVVVK அக்குக்க்கு 5 AB1 chimeric heavy chain full length nucleic acid sequence SEQ ID NO:6 AB1 chimeric heavy chain variable heavy chain nucleic acid sequence CAGTCGTTGGAGGAGTCCGGGGGAGACCTGGTCAAGCCTGAGGGATCCCTGACACTCACCTGCAAAGCCTCTGGATTCGACTTCAGTAGCGGCTACTGGATATGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTTGATCGCATGCATTTATGCTGGTACTAGTGGTAGTA CTTCCTACGCGAGCTGGGCGAGAGGCCGATTCACCATCTCCGAAACCTCGTCGACCACGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACTCGGCCACCTATTTCTGTGCGAGAAATCTTTACACTTACAATAGCTTGTGGGCCAGGGCACCCTGGTCACCGTCTCGAGC SEQ ID NO:7 Full amino acid sequence of the AB1 chimeric heavy chain. The human gamma-1 constant domain is underlined. QSLEESGGDLVKPEGSLTLTCKASGFDFSSGYWICWVRQAPGKGLELIACIYAGTSGSTSYASWARGRFTISETSSTTVTLQMTSLTAADSATYFCARNLYTYNSLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:8 AB1 chimeric heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QSLEESGGDLVKPEGSLTLTCKASGFDFSS GYWIC WVRQAPGKGLELIA CIYAGTSGSTSYASWARG RFTISETSSTTVTLQMTSLTAADSATYFCAR NLYTYNSL WGQGTLVTVSS SEQ ID NO:9 AB1HU humanized light chain full length nucleic acid sequence GACATCCAGATGACCCAGTTCCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTCCAGTCAGAGTGTTTATGATAACAACTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCTAAGCTCCTGATCTATACAGTATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTTATTACTGCCAAGGCACTTATTATAGTAGTGGTTGGAACTTTGCTTTCGGGCGGAGCAAGGTGG AGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCCCGTCACAAAGAGCTTCCAAGGGGAGAGTGT sequence number 10 AB1HU humanized light chain variable light chain nucleic acid sequence GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTCCAGTCAGAGTGTTATGATAACAACTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCTAAGCTCCTGATCTATACAGTATCCACTCTG GCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCACTTATTATAGTAGTGGTTGGAACTTTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA sequence number 11 Full amino acid sequence of the AB1HU humanized light chain. The human kappa constant domain is underlined. DIQMTQSPSTLSASVGDRVTITCQSSQSVYDNNWLAWYQQKPGKAPKLLIYTVSTLASGVPSRFSGSGSGTETLTISSLQPDDFATYYCQGTYYSSGWNFAFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 12 AB1HU humanized light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. DIQMTQSPSTLSASVGDRVTITC QSSQSVYDNNWLA WYQQKPGKAPKLLIY TVSTLAS GVPSRFSGSGSGTEFTLTISSLQPDDFATYYC QGTYYSSGWNFA FGGGTKVEIK sequence number 13 AB1HU humanized heavy chain full length nucleic acid sequence SEQ ID NO:14 AB1HU humanized heavy chain variable heavy chain nucleic acid sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCGACTTCAGTAGCGGCTACTGGATATGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTTGATCGCATGCATTTATGCTGGTACTAGTGGTAGT ACTTCCTACGCGAGCTGGGCGAGAGGCAGATTCACCATCTCCGAAACCTCCAAGAACACGGTGACTCTTCAAATGAACAGCCTGAGAGCCGAGGACTCGGCTGTGTATTACTGTGCGAGAAATCTTTACACTTACAATAGCTTGTGGGCCAGGGAACCCTGGTCACCGTCTCGAGC SEQ ID NO:15 AB1HU humanized heavy chain full length amino acid sequence. Human gamma 1 constant domain is underlined. EVQLVESGGGLVQPGGSLRLSCAASGFDFSSGYWICWVRQAPGKGLELIACIYAGTSGSTSYASWARGRFTISETSKNTVTLQMNSLRAEDSAVYYCARNLYTYNSLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG SEQ ID NO:16 AB1HU humanized heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. EVQLVESGGGLVQPGGSLRLSCAASGFDFSS GYWIC WVRQAPGKGLELIA CIYAGTSGSTSYASWARG RFTISETSKNTVTLQMNSLRAEDSAVYYCAR NLYTYNSL WGQGTLVTVSS SEQ ID NO:17 AB2 chimeric light chain full length nucleic acid sequence GATGTTGTGATCCACCAGACTCCAGCCTCCGTGTCTGCAGTTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTCAGAGCATTTACAGCTACTTAAACTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATGGTGCATCCAATCTGGCATCTGGGGTCTCATCGCGATTCAAAGGCAGTGGATCTGGGACAGAGTTCACTTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAATGTAGTTGGTTGAGTGGTGCTGGTAATGCTTTCGGCGGAGGGACCGAGGTGGTGG TCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 18 AB2 chimeric light chain variable light chain nucleic acid sequence GATGTTGTGATCACCAGACTCCAGCCTCCGTGTCTGCAGTTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTCAGAGCATTTACAGCTACTTAAACTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATGGTGCATCCAATCTGGCA TCTGGGGTCTCATCGCGATTCAAAGGCAGTGGATCTGGGACAGAGTTCACTTCCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAATGTAGTTGGTTGAGTGGTGCTGTTGGTAATGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA sequence number 19 Full amino acid sequence of the AB2 chimeric light chain. The human kappa constant domain is underlined. DVVMTQTPASVSAVVGGTVTIKCQASQSIYSYLNWYQQKPGQPPKLLIYGASNLASGVSSRFKGSGSGTEFTLTISDLECADAATYYCQCSWLSGAVGNAFGGGTEVVVK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 20 AB2 chimeric light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. DVVMTQTPASVSAVVGGTVTIKC QASQSIYSYLN WYQQKPGQPPKLLIY GASNLAS GVSSRFKGSGSGTTEFTLTISDLECADAATYYC QCSWLSGAVGNA FGGGTEVVVK sequence number 21 AB2 chimeric heavy chain full length nucleic acid sequence SEQ ID NO:22 AB2 chimeric heavy chain variable heavy chain nucleic acid sequence CAGGAGCAACTGGTGGAGTCCGGGGGAGGCCTGGTCCAGCCTGAGGGATCCCTGACACTCACCTGCACAGCTTCTGGATTCTCCTTCAGTAGCTACTGGATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGATGCATTACGACTGGTAGTGGT AGCACTTACTACGCGAGCTGGGCGAAGCGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACACGGCCACCTATTTCTGTACGAGAGCATTTGACTTGTGGGGCCCGGGGACCCTGGTCACCGTCTCGAGC SEQ ID NO:23 Full amino acid sequence of the AB2 chimeric heavy chain. The human gamma-1 constant domain is underlined. QEQLVESGGGLVQPEGSLTLTCTASGFSFSSYWMCWVRQAPGKGLEWIGCITTGSGSTYYASWAKRRFTISKTSSTTVTLQMTSLTAADTATYFCTRAFDLWGPGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:24 AB2 chimeric heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QEQLVESGGGLVQPEGSLLTTCTASGFSFS SYWMC WVRQAPGKGLEWIG CITTGSGSTYYASWAKR RFTISKTSSTTVTLQMTSLTAADTATYFCTR AFDL WGPGTLVTVSS SEQ ID NO:25 AB2HU humanized light chain full length nucleic acid sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTTACAGCTACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAAAGCAGTTGGTTGAGTGGTGCTGGTAATGCTTTCGGCGGAGGACCAAGGTGGAGA TCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 26 AB2HU humanized light chain variable light chain nucleic acid sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTTACAGCTACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAATCTGGCA TCTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAAAGCAGTTGGTTGAGTGGTGCTGTTGGTAATGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA SEQ ID NO:27 Full amino acid sequence of the AB2HU humanized light chain. The human kappa constant domain is underlined. DIQMTQSPSSLSASVGDRVTITCQASQSIYSYLNWYQQKPGKAPKLLIYGASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSSWLSGAVGNAFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:28 AB2HU humanized light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. DIQMTQSPSSLSASVGDRVTITC QASQSIYSYLN WYQQKPGKAPKLLIY GASNLAS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QSSWLSGAVGNA FGGGTKVEIK SEQ ID NO:29 AB2HU humanized heavy chain full length nucleic acid sequence SEQ ID NO:30 AB2HU humanized heavy chain variable heavy chain nucleic acid sequence CAGGAGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCTCCTTTAGCAGCTACTGGATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGATGCATTACGACTGGTAGTGGTA GCACTTACTACGCGAGCTGGGCGAAGCGCCGGTTCACCATCTCCAAAGACAATTCCAAGAACACGGTGACTCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTACGAGAGCATTTGACTTGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC SEQ ID NO:31 AB2HU humanized heavy chain full length amino acid sequence. Human gamma 1 constant domain is underlined. QEQLLESGGGLVQPGGSLRLSCTASGFFSSYWMCWVRQAPGKGLEWIGCITTGSGSTYYASWAKRRFTISKDNSKNTVTLQMNSLRAEDTAVYYCTRAFDLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG SEQ ID NO:32 AB2HU humanized heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QEQLLESGGGLVQPGGSLRLSCTASGFFSFS SYWMC WVRQAPGKGLEWIG CITTGSGSTYYASWAKR RFTISKDNSKNTVTLQMNSLRAEDTAVYYCTR AFDL WGQGTLVTVSS SEQ ID NO:33 AB3 chimeric light chain full length nucleic acid sequence CAAGTGCTGACCCAGACTCCATCTCCCGTGTCTGCAGCTGTGGGAGGCACAGTCAGCATCAGTTGCCAGTCCAGTCCGAGTGTTATAGTAACTACTTATCCTGGTTTCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTTATTAGCATCCACTCTGGCATCTGGGGTCCCTTGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTTCACCATCAGCGACGTGCAGTTGACGATGCTGCCACTTACTACTGTCAGGCGTTATATAGTAGTACTCGTGCTTTCGGCGGAGGGACCGAGGTGTGGTCA AACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 34 AB3 chimeric light chain variable light chain nucleic acid sequence CAAGTGCTGACCCAGACTCCATCTCCCGTGTCTGCAGCTGTGGGAGGCACAGTCAGCATCAGTTGCCAGTCCAGTCCGAGTGTTATAGTAACTACTTATCCTGGTTTCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTTATTAGCATCCACTCTGGCATCTGGGGTCCCTTGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTTCACCATCAGCGACGTGCAGTTGACGATGCTGCCACTTACTACTGTCAGGCGTTATATAGTAGTACTCGTGCTTTCGGCGGAGGGACCGAGGTGTGGTCAAA sequence no. 35 Full amino acid sequence of the AB3 chimeric light chain. The human kappa constant domain is underlined. QVLTQTPSPVSAAVGGTVSISCQSSPSVYSNYLSWFQQKPGQPPKLLIYYASTLASGVPSRFKGSGSGTQFTLTISDVQCDDAATYYCAGGYSSSTRAFGGGTEVVVK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 36 AB3 chimeric light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. QVLTQTPSPVSAAVGGTVSISC QSSPSVYSNYLS WFQQKPGQPPKLLIY YASTLAS GVPSRFKGSGSGTQFTLTISDVQCDDAATYYC AGGYSSSTRA FGGGTEVVVK sequence number 37 AB3 chimeric heavy chain full length nucleic acid sequence SEQ ID NO:38 AB3 chimeric heavy chain variable heavy chain nucleic acid sequence CAGGAGCAGGTGAAGGAGACCGGGGGAGGCCTGGTCCAGCCTGGGGGATCCCTGACACTCTCCTGCAAAGCCTCTGGATTTACCATCAGTAGCTATGGAGTGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATTGATTTTTCCTGGTATTGGTT TCAAAGACTACGCGAGCTGGGTGAATGGCCGATTCACCCTTCCAGCGACAACGCCCAGAACACTGTGGAACTTCAGATGAACAGTCTGACAGCGGCGGACACGGCCGCCTATTTCTGTGCGAGAGATTTGGACTTGTGGGGCCAAGGGACCCTCGTCACCGTCTCGAGC SEQ ID NO:39 Full amino acid sequence of the AB3 chimeric heavy chain. The human gamma-1 constant domain is underlined. QEQVKETGGGLVQPGGSLTLSCKASGFTISSYGVSWVRQAPGKGLEWIALIFPGIGFKDYASWVNGRFTLSSDNAQNTVELQMNSLTAADTAAYFCARDLDLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:40 AB3 chimeric heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QEQVKETGGGLVQPGGSLTLSCKASGFTIS SYGVS WVRQAPGKGLEWIA LIFPGIGFKDYASWVNG RFTLSSDNAQNTVELQMNSLTAADTAAYFCAR DLDL WGQGTLVTVSS SEQ ID NO:41 AB3HU humanized light chain full length nucleic acid sequence GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTCCAGTCCGAGTGTTATAGTAACTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATTATGCATCCACTCTGGCATCTGGGGTCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTTATTACTTGCAGGCGTTATATAGTAGTACTCGTGCTTTCGGCGGGACCAAGGTGGAGAAT AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 42 AB3HU humanized light chain variable light chain nucleic acid sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTCCAGTCCGAGTGTTATAGTAACTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATTATGCATCCACTCTGGCATCTGGGGTCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTTATTACTTGCAGGCGTTATATAGTAGTACTCGTGCTTTCGGCGGAGGACCAAGGTGGAGATCAAA sequence number 43 Full amino acid sequence of the AB3HU humanized light chain. The human kappa constant domain is underlined. DIQMTQSPSSLSASVGDRVTITCQSSPSVYSNYLSWYQQKPGKVKPLLIYYASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCAGGYSSSTRAFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 44 AB3HU humanized light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. DIQMTQSPSSLSASVGDRVTITC QSSPSVYSNYLS WYQQKPGKVPKLLIY YASTLAS GVPSRFSGSGSGTDFTLTISSLQPEDVATYYC AGGYSSSTRA FGGGTKVEIK sequence number 45 AB3HU humanized heavy chain full length nucleic acid sequence sequence number 46 AB3HU humanized heavy chain variable heavy chain nucleic acid sequence CAGGAGCAGGTGAAGGAGACCGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGCAGCTATGGAGTGAGCTGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGTCGCATTGATTTTTCCCGGATTGGTT TCAAAGACTACGCGAGCTGGGTGGAATGGCCGGTTCACCCTCTCCAGCGACAACGCCCAGAACACTGTGGAACTGCAAATGAACAGCCTGAGAGCCGAGGACAGGCCTATTACTGTGCGAGAGATTTGGACTTGTGGGGCCAGGGAACCCTGTCACCGTCTCGAGC sequence number 47 AB3HU humanized heavy chain full length amino acid sequence. Human gamma 1 constant domain is underlined. QEQVKETGGGLVQPGGSLRLSCAASGFTISSYGVSWVRQAPGKGLEWVALIFPGIGFKDYASWVNGRFTLSSDNAQNTVELQMNSLRAEDTAVYYCARDLDLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK sequence number 48 AB3HU humanized heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QEQVKETGGGLVQPGGSLRLSCAASGFTIS SYGVS WVRQAPGKGLEWVA LIFPGIGFKDYASWVNG RFTLSSDNAQNTVELQMNSLRAEDTAVYYCAR DLDL WGQGTLVTVSS sequence number 49 AB4 chimeric light chain full length nucleic acid sequence GCCCTTGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGAACATTTACAGCAATTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAGCCTCCTGATCTACCAGGCATCCACTCTGGCATCTGGGGTCTCATCGCGGTTCAGCGCAGTGGATATGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCGGTTATTAGTGCTGCCCTTAATACTTTCGCGGAGGGACCGAGGTGGTGGTC AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 50 AB4 chimeric light chain variable light chain nucleic acid sequence GCCCTTGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGAACATTTACAGCAATTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAGCCTCCTGATCTACCAGGCATCCACTCTGGCATCTGGGGTCTCATCGCGGTTCAGCGCAGTGGATATGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCGGTTATTAGTGCTGCCCTTAATACTTTCGGCGGAGGGACCGAGGTGTGGTCAAA sequence number 51 Full amino acid sequence of the AB4 chimeric light chain. The human kappa constant domain is underlined. ALVMTQTPSSVSAAVGGTVTINCQASQNIYSNLAWYQQKPGQPPSLLIYQASTLASGVSSRFSGSGYGTEFTLTISDLECADAATYYCQGGYYSAALNTFGGGTEVVVK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 52 AB4 chimeric light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. ALVMTQTPSSVSAAVGGTVTINC QASQNIYSNLA WYQQKPGQPPSLLIY QASTLAS GVSSRFSGSGYGTTEFTLTISDLECADAATYYC QGGYYSAALNT FGGGTEVVVK sequence number 53 AB4 chimeric heavy chain full length nucleic acid sequence SEQ ID NO:54 AB4 chimeric heavy chain variable heavy chain nucleic acid sequence CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGATTCTCCTCAGTAGCTATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATACATCGGATACATTGGTGATACTACTGGCATA GCCTACGCGAGCTGGGCGAATGGCCGATTCACCATCTCCAAAACCTCGACCACGGTGGATCTGAAGATCACCAGTCCGACAACCGGGGACACGGCCACCTATTTCTGTGCCAGAGGCTGGTCCTACTTAGACATCTGGGGCCAAGGGACCCTGGTCACCGTCTCGAGC SEQ ID NO:55 Full amino acid sequence of the AB4 chimeric heavy chain. The human gamma-1 constant domain is underlined. QSLEESGGRLVTPGTPLTLTCTVSGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKTSTTVDLKITSPTTGDTATYFCARGWSYLDIWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:56 AB4 chimeric heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QSLEESGGRLVTPGTPLTLTCTVSGFSLS SYAMS WVRQAPGKGLEYIG YIGDTTGIAYASWANG RFTISKTSTTVDLKITSPTTGDTATYFCAR GWSYLDI WGQGTLVTVSS SEQ ID NO:57 AB4HU humanized light chain full length nucleic acid sequence GCCCTTGTGATCGACCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGGCCAGTCAGAACATTTACAGCAATTTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATCAGGCCTCCACTCTGGCATCTGGGGTCCATCTCGGTTCAGTGGCAGTGGATATGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAGGCGGTTATTATATGCTGCCCTTAAATACTTTCGGCGAGGACCAAGGTGGAGAAT AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence number 58 AB4HU humanized light chain variable light chain nucleic acid sequence GCCCTTGTGATCCACCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGGCCAGTCAGAACATTTACAGCAATTTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATCAGGCCTCCACTCTGG CATCTGGGGTCCATCTCGGTTCAGTGGCAGTGGATATGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAGGCGGTTATTATATGTGCTGCCCTTAATACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA sequence number 59 Full amino acid sequence of the AB4HU humanized light chain. The human kappa constant domain is underlined. ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPKGVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence number 60 AB4HU humanized light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. ALVMTQSPSSLSASVGDRVTITC QASQNIYSNLA WYQQKPGKVPKLLIY QASTLAS GVPSRFSGSGYGTDFTLTISSLQPEDVATYYC QGGYYSAALNT FGGGTKVEIK sequence no.61 AB4HU humanized heavy chain full length nucleic acid sequence sequence no.62 AB4HU humanized heavy chain variable heavy chain nucleic acid sequence GAGGTGCAGCTGGTGGAGTCTGGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCTCCCTCAGTAGCTATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGCTACATTGGTGATACTACTGGCATAG CCTACGCGAGCTGGGCGAATGGCAGATTCACCATCTCCAAAGACATACCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGCTGGTCCTACTTAGACATCTGGGGCCAAGGGACCCTGGTCACCGTCTCGAGC sequence no. 63 AB4HU humanized heavy chain full length amino acid sequence. Human gamma 1 constant domain is underlined. EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPKGGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG sequence no. 64 AB4HU humanized heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. EVQLVESGGGLVQPGGSLRLSCTASGFSLS SYAMS WVRQAPGKGLEYIG YIGDTTGIAYASWANG RFTISKDNTKNTVDLQMNSLRAEDTAVYCAR GWSYLDI WGQGTLVTVSS sequence number 65 AB5 chimeric light chain full length nucleic acid sequence GCCTATGATATGACCCAGACTCCATCCTCCGTGTCTGCCGCTGTGGGAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGCATTAACAACCAACTATCCTGGTATCAGCAGAAACCAGGGGCAGCCTCCCAAGCTCCTGATCTATGGTGCATCCACTCTGG CATCTGGGGTCCATCGCGGTTCACCGGCAGTGGATCTGGGACAGAGTTCACTTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTCATGTTCATTATTGCAGTGGTGGTAGTTGTTTTTGGGCTTTCGGCGGAGGGACCGAGGTGGTG GTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence no.66 AB5 chimeric light chain variable light chain nucleic acid sequence GCCTATATGACCCAGACTCCATCCTCCGTGTCTGCCGCTGTGGGAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGAGCATTAACAACCAACTATCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATGGTGCATCCACTCTGGCAT CTGGGGTCCCATCGCGGTTCACCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTCATGTTCATTATTGCAGTGGTGGTAGTTGTTTTTGGGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA SEQ ID NO:67 Full amino acid sequence of the AB5 chimeric light chain. The human kappa constant domain is underlined. AYDMTQTPSSVSAAVGGTVTINCQASQSINNQLSWYQQKPGQPPKLLIYGASTLASGVPSRFTGSGSGTEFTLTISGVQCDDAATYYCHVHYCSGGSCFWAFGGGTEVVVK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:68 AB5 chimeric light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. AYDMTQTPSSVSAAVGGTVTINC QASQSINNQLS WYQQKPGQPPKLLIY GASTLAS GVPSRFTGSGSGTEFTLTISGVQCDDAATYYC HVHYCSGGSCFWA FGGGTEVVVK SEQ ID NO:69 AB5 chimeric heavy chain full length nucleic acid sequence SEQ ID NO:70 AB5 chimeric heavy chain variable heavy chain nucleic acid sequence CAGGAGCAGTTGGAGGAGTCCGGGGGAGACCTGGTCAAGCCTGAGGGATCCCTGACACTCACCTGCACAGCCTCTGGATTCTCCTTCAGTAGCAGCCACTGGATATGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTTATACTGGTAGTATTGATGTCTTTT ACTGTGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAACCCTCGTCGACCACGGTGACTCTGCAAGTGCCCAGTCTGACAGCCGCGGACACGGCCACCTATTTCTGTGCGAGAGCCGCTAATACTGATACTACCTACTTTAACTTGTGGGGCCCAGGGACCCTCGTCACCGTCTCGAGC SEQ ID NO:71 Full amino acid sequence of the AB5 chimeric heavy chain. The human gamma-1 constant domain is underlined. QEQLEESGGDLVKPEGSLTLTCTASGFSFSSSHWICWVRQAPGKGLEWIACIYTGSIDVFYCASWAKGRFTISKPSSTTVTLQVPSLTAADTATYFCARAANTDTTYFNLWGPGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:72 AB5 chimeric heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. QEQLEESGGDLVKPEGSLTLTCTASGFSFSS SHWIC WVRQAPGKGLEWIA CIYTGSIDVFYCASWAKG RFTISKPSSTTVTLQVPSLTAADTATYFCAR AANTDTTYFNL WGPGTLVTVSS SEQ ID NO:73 AB5HU humanized light chain full length nucleic acid sequence GCCTATGATATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAAATTGCCAGGCCAGTCAGAGCATTAACAACCAACTATCCTGGTTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATGGTGCATCCACTCTGGCATCTGGGGTCCATCTCGGTTCACCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTTATTACTGTCATGTTCATTTATTGCAGTGGTGGTAGTTTTTGGGCTTTCGCGGGGACCAAGGTGGAG ATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGGTTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCAGGGCCTGAGCCCGTCACAAAGAGCTTCACAGGGGAGAGTGT sequence no. 74 AB5HU humanized light chain variable light chain nucleic acid sequence GCCTATGATATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGCCAGTCAGCATTAACACCAACTATCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCTCCTGATCTATGGTGCATCCACTCTGGCAT CTGGGGTCCCATCTCGGTTCACCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCATGTTCATTATTGCAGTGGTGGTAGTTGTTTTTGGGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA sequence no. 75 AB5HU humanized light chain full length amino acid sequence. Human kappa constant domain is underlined. AYDMTQSPSSLSASVGDRVTINCQASQSINNQLSWYQQKPGKVKPLLIYGASTLASGVPSRFTGSGSGDTFTLTISSLQPEDVATYYCHVHYCSGGSCFWAFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC sequence no. 76 AB5HU humanized light chain variable light chain amino acid sequence. Complementarity determining regions are underlined. AYDMTQSPSSLSASVGDRVTINC QASQSINNQLS WYQQKPGKVPKLLIY GASTLAS GVPSRFTGSGSGTDFTLTISSLQPEDVATYYC HVHYCSGGSCFWA FGGGTKVEIK sequence number77 AB5HU humanized heavy chain full length nucleic acid sequence sequence no. 78 AB5HU humanized heavy chain variable heavy chain nucleic acid sequence GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCAGCCACTGGATATGCTGGGTCCGCCAGGCTCAGGGAAGGGGCTGGAGTGGATCGCATGCATTTATACTGGTAGTATTGATGTCTTTTAC TACGCGAGCTGGGCGAAAGGCCGGTTCACCATCTCCGAGAGAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGAGCGCTAATACTGATACTACCTACTTTAACTTGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC sequence no. 79 AB5HU humanized heavy chain full length amino acid sequence. Human gamma 1 constant domain is underlined. EVQLLESSGGLVQPGGSLRLSCAASGFTFSSSHWICWVRQAPGKGLEWIACIYTGSIDVFYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYCARAANTDTTYFNLWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG sequence no.80 AB5HU humanized heavy chain variable heavy chain amino acid sequence. Complementarity determining regions are underlined. EVQLLESSGGGLVQPGGSLRLSCAASGFTFSS SHWIC WVRQAPGKGLEWIA CIYTGSIDVFYYASWAKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR AANTDTTYFNL WGQGTLVTVSS

Claims

1. An isolated mAb or antigen-binding fragment thereof that has binding specificity for human PD-1, An isolated mAb or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:60 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:64; a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:12 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:16; a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:28 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:32; a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:44 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:48; or a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:76 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:

80.

2. 2. The isolated mAb or antigen-binding fragment of claim 1, having a binding affinity to human PD-1 with a Kd of 70 nM or less.

3. 2. The isolated mAb or antigen-binding fragment of claim 1, which exhibits one or more functional properties selected from high affinity binding to human PD-1, inhibition of binding of human PD-L1 to PD-1, enhancing T cell activation, stimulating an antibody response, reversing the suppressive function of immune suppressor cells, or a combination thereof.

4. 4. The isolated mAb or antigen-binding fragment of claim 3, wherein the enhanced T cell activation comprises T cell proliferation, IFN-γ and / or IL-2 secretion, or a combination thereof.

5. 2. The isolated mAb or antigen-binding fragment thereof of claim 1 , wherein the isolated mAb comprises a humanized antibody, a chimeric antibody, or a recombinant antibody.

6. 2. The isolated mAb or antigen-binding fragment thereof of claim 1 , wherein the isolated antibody comprises an IgG.

7. 2. The isolated mAb or antigen-binding fragment thereof of claim 1, wherein the antigen-binding fragment comprises an Fv, Fab, F(ab')2, scFv or scFV2 ​​fragment.

8. 2. The isolated mAb or antigen-binding fragment thereof of claim 1 , wherein the isolated mAb comprises a bispecific antibody, a trispecific antibody, or a multispecific antibody.

9. An IgG1 heavy chain for the isolated mAb or antigen-binding fragment of claim 1, comprising: An IgG1 heavy chain comprising the amino acid sequence set forth in SEQ ID NO:63, SEQ ID NO:15, SEQ ID NO:31, SEQ ID NO:47, or SEQ ID NO:

79.

10. A kappa light chain for the isolated mAb or antigen-binding fragment of claim 1, comprising: A kappa light chain comprising the amino acid sequence set forth in SEQ ID NO:59, SEQ ID NO:11, SEQ ID NO:27, SEQ ID NO:43, or SEQ ID NO:

75.

11. A variable light chain for the isolated mAb or antigen-binding fragment of claim 1, comprising: A variable light chain comprising the amino acid sequence set forth in SEQ ID NO:60, SEQ ID NO:12, SEQ ID NO:28, SEQ ID NO:44, or SEQ ID NO:

76.

12. A variable heavy chain for the isolated mAb or antigen-binding fragment of claim 1, comprising: A variable heavy chain comprising the amino acid sequence set forth in SEQ ID NO:64, SEQ ID NO:16, SEQ ID NO:32, SEQ ID NO:48, or SEQ ID NO:

80.

13. 13. An isolated nucleic acid encoding the isolated mAb or antigen-binding fragment of claim 1, the IgG1 heavy chain of claim 9, the kappa light chain of claim 10, the variable light chain of claim 11, or the variable heavy chain of claim 12.

14. 14. An expression vector comprising the isolated nucleic acid of claim 13.

15. 14. A host cell comprising the nucleic acid of claim 13, wherein the host cell is a prokaryotic or eukaryotic cell.

16. A method for producing an antibody, comprising culturing the host cell of claim 15 so that the antibody is produced.

17. 10. An immunoconjugate comprising the isolated mAb or antigen-binding fragment thereof of claim 1 and a drug unit, The covalent bond is selected from an ether bond, an amine bond, an amide bond, a disulfide bond, an imide bond, a sulfone bond, a phosphate bond, or a combination thereof; immune complex.

18. 18. The immunoconjugate of claim 17, wherein the drug unit is selected from a cytotoxic agent, an immunomodulatory agent, or a combination thereof.

19. 19. The immunoconjugate of claim 18, wherein the cytotoxic agent is selected from a growth inhibitory agent or a chemotherapeutic agent selected from the group consisting of tubulin binding agents, DNA intercalators, DNA alkylators, enzyme inhibitors, immunomodulators, antimetabolites, radioisotopes, or combinations thereof.

20. 19. The immunoconjugate of claim 18, wherein the cytotoxic agent is selected from calicheamicin, ozogamicin, monomethyl auristatin E, emtansine, derivatives or combinations thereof.

21. 20. The immunoconjugate of claim 18, wherein the immunomodulatory agent activates or suppresses an immune cell, a T cell, a NK cell, a B cell, a macrophage, or a dendritic cell.

22. 18. A pharmaceutical composition comprising the isolated mAb or antigen-binding fragment thereof of claim 1 or the immunoconjugate of claim 17, and a pharma- ceutically acceptable carrier.

23. 23. The pharmaceutical composition of claim 22, further comprising a chemotherapeutic agent, a growth inhibitory agent, a drug unit selected from the group of a calicheamicin, an antimitotic agent, a radioisotope, a toxin, a therapeutic agent, or a combination thereof.

24. 1. A pharmaceutical composition for treating a subject having cancer, comprising:

2. A method for treating a patient comprising administering to said patient an effective amount of the isolated mAb or antigen-binding fragment thereof of claim 1, the cancer comprises cells that express PD-1; Pharmaceutical composition.

25. 25. The pharmaceutical composition of claim 24, wherein the cancer comprises breast cancer, colon cancer, pancreatic cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, non-small cell lung cancer, glioma, esophageal cancer, nasopharyngeal cancer, anal cancer, rectal cancer, gastric cancer, bladder cancer, cervical cancer, or brain cancer.

26. 25. The pharmaceutical composition of claim 24, wherein the treatment comprises co-administering an effective amount of a therapeutic agent, the therapeutic agent comprising an antibody, a chemotherapeutic agent, an enzyme, an anti-estrogen, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a cell cycle inhibitor, a DNA, RNA, or protein synthesis inhibitor, a RAS inhibitor, or a combination thereof.

27. The therapeutic agent is selected from the group consisting of capecitabine, cisplatin, cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, cyclophosphamide, mustine, vincristine, procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, epirubicin, pemetrexed, folinic acid, gemcitabine, oxaliplatin, irinotecan, topotecan, camptothecin, docetaxel, paclitaxel, fulvestrant, tamoxifen, letrozole, exemestane, anastrozole, aminoglutethimide, testosterone, and the like.

27. The pharmaceutical composition of claim 26, comprising thiazide, vorozole, formestane, fadrozole, erlotinib, lafatinib, dasatinib, gefitinib, osimertinib, vandertanib, afatinib, imatinib, pazopinib, lapatinib, sunitinib, nilotinib, sorafenib, nab-palitaxel, everolimus, temsirolimus, dabrafenib, vemurafenib, trametinib, vintafolide, apatinib, crizotinib, periforsine, olaparib, bortezomib, tofacitinib, trastuzumab, or derivatives or combinations thereof.

28. 25. The pharmaceutical composition of claim 24, wherein the subject is a human.

Images